FromAstraZeneca ([email protected])
Subject (126)Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
Preheader (125)Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
Arial
Text Analysis
Body Words197
Subject Words18
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px
X-Spam Score0.4
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening
